LDSYF

 
Ordinary Shares International Reporting
OTCQB
Contact Info
  • 1130 Pender Street, West
  • Suite 820
  • Vancouver, BC V6E 4A4
  • Canada

Business Description


Update Company Profile
 
Financial Reporting/Disclosure
Reporting Status International Reporting: Canadian Securities Exchange
Audited Financials Audited
Latest Report Sep 30, 2016 Interim Financial Report
CIK 0001640152
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Incorporated In: British Columbia, Canada
Year of Inc. 2010
Employees Not Available
Company Officers/Contacts
Brad Eckenweiler CEO
James Pakulis President
Yanika Silina CFO
Dr. John Sanderson Chief Med. Officer
Company Directors
Brad Eckenweiler
James Pakulis
David Velisek
Service Providers
Accounting/Auditing Firm
Dale Matheson Carr-Hilton Labonte LLP
1140 West Pender St.
Suite 1500 and 1700
Vancouver, BC, V6E 4G1
Canada
 
Securities Counsel
O'Neill Law Corporation
595 Howe Street
Suite 704
Vancouver, BC, V6C 2T5
Canada
 
Investor Relations Firm

Not Available
LDSYF Security Details
Share Structure
Market Value1 $24,289,989 a/o Feb 17, 2017
Authorized Shares Unlimited a/o Feb 07, 2017
Outstanding Shares 52,473,512 a/o Feb 07, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 46,160,012 a/o Feb 07, 2017
Par Value Not Available
Shareholders
Shareholders of Record 26 a/o Feb 07, 2017
Non US Stock Exchange Listing
LDS - Canadian Securities Exchange - Qualified
Short Selling Data
Short Interest 25,713 (26.61%)
Jan 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security